Short Communication

High-Fat Diet Feeding Alters Expression of Hepatic Drug-Metabolizing Enzymes in Mice[□]

Received February 27, 2017; accepted April 19, 2017

ABSTRACT

Medical conditions accompanying obesity often require drug therapy, but whether and how obesity alters the expression of drug-metabolizing enzymes and thus drug pharmacokinetics is poorly defined. Previous studies have shown that high-fat diet (HFD) feeding and subsequent obesity in mice lead to altered expression of transcriptional regulators for cytochrome P450 CYP2D6, including hepatocyte nuclear factor 4 α (HNF4 α , a transcriptional activator of CYP2D6) and small heterodimer partner (SHP, a transcriptional repressor of CYP2D6). The objective of this study was to examine whether diet-induced obesity alters CYP2D6 expression by modulating HNF4 α and SHP expression. Male CYP2D6-humanized transgenic (Tg-CYP2D6) mice were fed with HFD or matching control diet for 18 weeks. Hepatic mRNA expression of CYP2D6 decreased to a

small extent in the HFD group (by 31%), but the differences in CYP2D6 protein and activity levels in hepatic S9 fractions were found insignificant between the groups. Although hepatic SHP expression did not differ between the groups, HNF4 α mRNA and protein levels decreased by ~30% in the HFD group. Among major mouse endogenous cytochrome P450 genes, Cyp1a2 and Cyp2c37 showed significant decreases in the HFD group, whereas Cyp2e1 expression did not differ between groups. Cyp2b10 and Cyp3a11 expression was higher in the HFD group, with corresponding 2.9-fold increases in hepatic CYP3A activities in HFD-fed mice. Together, these results suggest that obesity has minimal effects on CYP2D6-mediated drug metabolism, although it modulates the expression of mouse endogenous P450s in a gene-specific manner.

Introduction

Obesity is a prevalent medical condition associated with increased incidences of chronic comorbidities, such as diabetes, cardiovascular diseases, and nonalcoholic fatty liver diseases (Fujioka, 2015), which often require drug treatment. Yet, our understanding of whether and how obesity alters the rate and extent of drug disposition, especially hepatic drug metabolism, remains incomplete. Clinical reports suggest that obesity leads to altered hepatic drug metabolism in a metabolic pathway-specific manner; however, the directional changes for cytochrome P450 (P450)-mediated metabolism are for the most part inconclusive.

CYP2D6 is a major drug-metabolizing enzyme responsible for metabolizing ~25% of marketed drugs. Previous studies have shown important roles for transcriptional regulation of CYP2D6 (Koh et al., 2014; Pan et al., 2015). Hepatocyte nuclear factor 4 α (HNF4 α) transactivates CYP2D6 promoter by binding to a proximal promoter region, whereas small heterodimer partner (SHP) represses CYP2D6 expression by inhibiting HNF4 α transactivation of CYP2D6 promoter (Koh et al., 2014). Of interest, obesity leads to altered expression/activity of different transcriptional regulators of CYP2D6. Specifically, high-fat diet (HFD) feeding in mice has been shown to decrease HNF4 α expression (Xu et al., 2015) and increase SHP protein levels (Miao et al., 2009). However, whether these changes affect CYP2D6 expression

remains unclear. In this study, we examined whether HFD feeding modulates CYP2D6-mediated drug metabolism by using CYP2D6-humanized transgenic (Tg-CYP2D6) mice. Furthermore, we explored how endogenous mouse P450 gene expression is altered in HFD-fed mice to provide insights into the effects of obesity on hepatic drug metabolism in general.

Materials and Methods

Animals. Tg-CYP2D6 mice were previously described (Koh et al., 2014). Male Tg-CYP2D6 mice (6–8 week-old; $n = 7–9$ per group) were fed with either Adjusted Calories Diet (HFD; TD.88137, Teklad; Envigo, Huntingdon, Cambridgeshire, United Kingdom) or a matching low-fat control diet (TD.08485, Teklad) for 18 weeks in specific pathogen-free environment with 12-hour light and dark cycles. The mice had access to the diet and water ad libitum. All procedures were approved by the Institutional Animal Care and Use Committee in the University of Illinois at Chicago.

RNA Isolation and Quantitative Real Time-PCR. Total RNAs were isolated from mouse liver tissues using Trizol (Life Technologies/Thermo Fisher Scientific, Sunnyvale, CA) and used as template for cDNA synthesis using High-Capacity cDNA Reverse Transcription Kit (Life Technologies/Thermo Fisher Scientific). Quantitative real time-PCR (qRT-PCR) was performed using StepOnePlus Real-Time PCR System (Thermo Fisher Scientific). Predesigned gene expression assays and primers were listed in supplemental data (Supplemental Table 1). The relative mRNA expression level was determined after normalizing the expression levels by those of mouse Gapdh ($2^{-\Delta\Delta C_t}$ method).

Western Blot. Mouse liver lysates were resolved using 4–20% Mini-PROTEAN TGX Precast Protein Gels (Bio-Rad, Hercules, CA). CYP2D6 (cat. no. 458246, BD Gentest; BD, Franklin Lakes, NJ); HNF4 α (K9218; R&D Systems, Minneapolis, MN); SHP (sc-30169; Santa Cruz Biotechnology, Dallas, TX); and β -actin (A1978; Sigma-Aldrich, St. Louis, MO) primary antibodies were used. SuperSignal West Pico Chemiluminescent Substrate (34080;

This work was supported by the National Institutes of Health [Grants R01HD065532 and R01GM112746]. This research was supported in part by a Graduate Student Fellowship Award from the American Association of Pharmaceutical Scientists Foundation.

<https://doi.org/10.1124/dmd.117.075655>.

[□]This article has supplemental material available at dmd.aspetjournals.org.

ABBREVIATIONS: HFD, high-fat diet; HNF4 α , hepatocyte nuclear factor 4 α ; P450, cytochrome P450; PXR, pregnane X receptor; qRT-PCR, quantitative real time-PCR; SHP, small heterodimer partner; Tg-CYP2D6, CYP2D6-humanized transgenic mouse.

ThermoFisher, Rockford, IL) was used for detection. The images were recorded and analyzed using FluorChem E system and AlphaView software (ProteinSimple, San Jose, CA).

Measurement of CYP2D6 and CYP3A Activities. Liver tissues (~200 mg) were accurately weighed for S9 preparation. The samples were homogenized on ice using tissue homogenizer (PowerGen 125; Fisher Scientific) in 0.05 M Tris-HCl (pH 7.0) buffer containing 150 mM KCl, 2 mM EDTA, and protease inhibitor cocktail (P8340; Sigma-Aldrich). The homogenate was centrifuged at 9000g for 20 minutes at 4°C. The supernatant was collected and volume measured. Protein content in S9 fraction was measured by BCA protein assay (Pierce Biotechnology, Rockford, IL). Total S9 protein amount per liver = (S9 protein concentration × S9 volume / liver weight used for S9 preparation) × total liver weight. CYP2D6 activity was measured as previously described (Koh et al., 2014). Briefly, for the measurement of CYP2D6 activity, S9 fractions (~3 mg/ml) were incubated with debrisoquine (200 μM) for 15 minutes, and the reaction was stopped by adding 1 vol of ice-cold acetonitrile with internal standard (paraxanthine, 800 ng/ml). The concentration of 4-hydroxydebrisoquine was measured by liquid chromatography–tandem mass spectroscopy (LC-MS/MS) (Agilent 6410 Triple Quadrupole LC/MS) using electrospray ion source (ESI) in positive ion mode, detecting $[M+H]^+$ ions. Multiple reaction monitoring (MRM) data acquisition was employed: m/z = 192.3/132.2 for 4-hydroxydebrisoquine and m/z = 181.1/124.1 for the internal standard. For CYP3A activity, mouse liver S9 (~0.6 mg/ml) was incubated with triazolam (23 μM) for 5 minutes and the reaction was stopped by adding 1 vol of ice-cold acetonitrile containing internal standard (1-hydroxytriazolam-D₄, 40 ng/ml). The concentrations of 1-hydroxytriazolam were measured by LC-MS/MS (Agilent 1200 HPLC with AB Sciex QTRAP 5500 System) using ESI source in positive ion mode, detecting $[M+H]^+$ ions. MRM for 1-hydroxytriazolam and 1-hydroxytriazolam-D₄ were m/z = 359.4/176.3 and m/z = 363.2/335.0, respectively.

Statistical Analysis. All data were presented as mean ± S.D. Statistical analyses for qRT-PCR and Western blot results were performed using Student's *t* test between control and HFD group using Prism 6.0 (Graphpad Software, Inc., La Jolla, CA). For correlation study, Pearson's correlation test and linear regression was used as appropriate.

Results and Discussion

Diet-Induced Obesity Model in Tg-CYP2D6 Mice. Tg-CYP2D6 mice have been used as an *in vivo* model for studying transcriptional regulation of CYP2D6 (Koh et al., 2014; Pan et al., 2015). To evaluate the effect of obesity on CYP2D6 expression *in vivo*, we first established a diet-induced obesity model in Tg-CYP2D6 mice by chronic HFD feeding. Male Tg-CYP2D6 mice were fed with either HFD or a matching control diet for 18 weeks *ad libitum*. Mice in the HFD group gained more weight than those from control diet group since week 8 (Supplemental Fig. 1A). The livers from HFD-fed mice were pale and enlarged, suggesting hepatic steatosis (Supplemental Fig. 1B). The mouse liver weight was 1.68 ± 0.38 and 3.62 ± 1.02 g in control and HFD groups, respectively (n = 6–8 per group, p < 0.001). Liver-to-body weight ratio was also increased significantly in HFD mice (Supplemental Fig. 1C). Although the S9 protein yield per gram of liver was 25% lower in HFD-fed mice, the total protein amount in S9 fractions per liver was ~60% higher in the group (Supplemental Fig. 1D), suggesting increased numbers and/or sizes of parenchymal cells upon HFD. In humans, the liver volume (determined by using magnetic resonance imaging) in obese-to-morbidly obese subjects was 1.25- to 1.5-fold larger (Lewis et al., 2006; Bian et al., 2014) than that in subjects with normal body weight (Johnson et al., 2005). Of note, the extent of increases in liver size is smaller in humans than in mice, and the relative contribution between accumulating fats and the expansion of parenchymal cells to increased liver size in humans is unclear.

CYP2D6 Expression Did Not Differ between HFD and Control Mice. Previous reports showed that HFD decreases HNF4α expression by inducing microRNA-34a expression (Xu et al., 2015) and that HFD feeding increases SHP protein levels by enhancing SHP protein stability

(Miao et al., 2009). To validate if expression of these transcription regulators is altered in obese Tg-CYP2D6 mice, hepatic mRNA and protein levels of HNF4α and SHP were examined in HFD-fed Tg-CYP2D6 mice. HNF4α mRNA and protein levels decreased significantly (35% and 33%, respectively) in the HFD group of Tg-CYP2D6 mice (Fig. 1A). This was accompanied by decreased expression of known HNF4α target genes in the liver [i.e., *hes* family basic helix-loop-helix (bHLH) transcription factor 6 (*Hes6*), organic anion-transporting polypeptides 1a1 (*Oatp1a1*), and phosphoenolpyruvate carboxykinase 1 (*Pck1*)] (Hayhurst et al., 2001; Martinez-Jimenez et al., 2010; Fang et al., 2012) (Fig. 1B). Contrary to the previous report, SHP mRNA and protein levels did not differ between HFD and control groups (Supplemental Fig. 2). Differences in mouse study design (i.e., CV57 versus Tg-CYP2D6 with C57/BL background) may explain the apparent discrepancy. Also, although a matching low-fat control diet was used in this study, the diet used for the control group was not specified in the previous study. Differences in diet and strain have been shown to result in differential composition of gut microbiota in mice (Ussar et al., 2015). Accumulating evidence indicates that gut microbiota modulates multiple aspects of physiology, including the composition of bile acids and subsequent intestinal farnesoid X receptor (FXR) signaling (Wahlstrom et al., 2016). The products of intestinal FXR signaling, such as fibroblast growth factor 15, can alter SHP protein stability in the liver (Miao et al., 2009).

Importantly, hepatic mRNA levels of CYP2D6 decreased to a small extent in the HFD group (Fig. 1C). However, hepatic CYP2D6 protein and activity levels did not differ between HFD and control groups (Fig. 1, D and E). The total CYP2D6 activity per liver was even higher in HFD-fed mice owing to the greater S9 protein amounts (Fig. 1F). Of interest, results from currently available clinical data suggest that the metabolic rates of CYP2D6 substrate drugs are similar in obese and nonobese subjects. For example, Cheymol et al. (1995) reported no differences in the clearance of dexfenfluramine (a CYP2D6 substrate of hepatic extraction ratio ~0.3) between obese and nonobese subjects after intravenous infusion. It appears plausible that the obesity-induced increase in liver size observed in humans does not involve the expansion of parenchymal cells, unlike in mice.

Obesity Had Differential Effects on Mouse Endogenous P450s. Considering that HNF4α is a global regulator of hepatic genes, including those encoding P450s (Jover et al., 2009), we examined the mRNA expression of representative mouse endogenous P450s. qRT-PCR results showed pathway-dependent changes in their expression in HFD-fed mice (Fig. 2A and Supplemental Fig. 3). *Cyp1a2* and *Cyp2c37* expression decreased significantly in HFD-fed mice, whereas *Cyp2e1* expression did not differ between the groups. As for mouse endogenous *Cyp2ds*, expression of *Cyp2d26* (the most abundant hepatic *Cyp2d* isoform) did not change upon HFD feeding, whereas other isoforms (*Cyp2d10*, *Cyp2d22*, and *Cyp2d40*) decreased significantly. Of note, *Cyp3a11* expression increased significantly in HFD-fed mice (Fig. 2A). Although this is consistent with previous reports (Kim et al., 2004; Kudo et al., 2009; Geng et al., 2015), others have reported decreased hepatic *Cyp3a11* expression or activity upon HFD feeding in mice (Yoshinari et al., 2006; Ghose et al., 2011; Wahlang et al., 2014). Differences in diet composition and housing condition may have contributed to the discrepancy. For instance, feeding of mice with HFD containing saturated fat (as in our HFD) induced *Cyp3a11* expression, but HFD containing unsaturated fat decreased it (Geng et al., 2015). Also, mice housed in conventional conditions have been reported to exhibit low-grade inflammation in the liver on HFD feeding, although mice in a specific pathogen-free environment do not (Muller et al., 2016). Hepatic inflammation is known to cause CYP3A downregulation in humans and mice by downregulating the expression and function of transcription

Fig. 1. Expression and activity of HNF4 α and CYP2D6 in HFD-fed Tg-CYP2D6 mice. Liver tissues were collected from Tg-CYP2D6 mice after 18 weeks of HFD or matching control (Ctrl) diet feeding. (A) Relative Hnf4 α mRNA levels (left) determined by qRT-PCR were normalized by that of control group. Relative HNF4 α protein levels (right) were normalized against β -actin band intensities. (B) Hepatic mRNA levels of representative HNF4 α target genes were determined by qRT-PCR and normalized by that of control group. (C) Hepatic mRNA level of CYP2D6 was normalized by that of control group. (D) CYP2D6 protein level in hepatic S9 fraction (right) was determined using Western blot normalized against β -actin band intensities. (E) CYP2D6 activity in mouse liver S9 fraction was measured using debrisoquine as a substrate. CYP2D6 activity is presented as 4-hydroxydebrisoquine formation rate per mg S9 protein. (F) Total CYP2D6 activity per liver was the product of CYP2D6 activity per mg S9 protein and total S9 protein level per liver. $N = 6-8$ per group for qRT-PCR and activity assay. Data shown are mean $\pm$ S.D. NS, not significant, * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$.

factors for CYP3A4 (Aitken et al., 2006). Indeed, the hepatic expression of inflammation markers (e.g., IL1 β , IL6, or TNF α) was increased in HFD-fed mice in the studies that observed decreased Cyp3a11 expression (Yoshinari et al., 2006; Ghose et al., 2011; Wahlang et al., 2014). Of note, hepatic expression of IL1 β , IL6, and TNF α did not differ between HFD and control groups in our study (Supplemental Fig. 4).

Considering that Cyp3a11 is a mouse homolog of CYP3A4, the most important drug-metabolizing enzyme in humans, the changes in

Cyp3a11 expression were further verified at the enzyme activity level using triazolam as a probe substrate. Hepatic CYP3A activity in mouse S9 fraction was significantly higher in mice fed with HFD (Fig. 2B). CYP3A activity correlated well with Cyp3a11 mRNA levels ($r = 0.81$) (Fig. 2C), suggesting that increased CYP3A enzyme activity in HFD mice is in part attributable to enhanced Cyp3a11 expression. Pregnane X receptor (PXR) and constitutive androstane receptor (CAR) are ligand-activated nuclear receptors and major transcriptional activators of

Fig. 2. Mouse endogenous P450 expression upon HFD feeding in Tg-CYP2D6 mice. Liver tissues were collected from mice after 18 weeks of HFD or matching control (Ctrl) diet feeding. (A) Hepatic mRNA levels of drug-metabolizing P450s were measured using qRT-PCR and normalized to those of the control group. (B) Mouse CYP3A activity in liver S9 fraction was measured using triazolam as a substrate. CYP3A activity is presented as 1-hydroxytriazolam formation rate. (C) Mouse CYP3A activity correlated with Cyp3a11 relative mRNA level (Pearson correlation efficiency $r = 0.81$, $p < 0.001$). (D) Hepatic mRNA levels of Pxr and Car were determined using qRT-PCR and normalized by those of the control group. $N = 7-8$ per group. Data shown are mean $\pm$ S.D. NS, not significant, * $p < 0.05$, ** $p < 0.01$.

Cyp3a11 expression in mice (Li et al., 2016). qRT-PCR results showed that mRNA expression of neither Pxr nor Car increased in HFD-fed mice (Fig. 2D), suggesting that altered expression of these transcription factors is not responsible for Cyp3a11 induction in HFD-fed mice. Whether HFD feeding modulates (e.g., increases) the hepatic levels of the endogenous ligands of PXR or CAR (e.g., bilirubin, bile acids, and steroid hormones) (Bjorkholm et al., 2009) remains unclear. Of interest, HFD feeding was shown to cause adrenal cortical hyperplasia in mice, leading to higher plasma levels of corticosteroids (i.e., PXR activators) (Swierczynska et al., 2015).

Clinical evidence is conflicting on whether obesity affects CYP3A4-mediated drug metabolism in humans. A population pharmacokinetic analysis of midazolam [a CYP3A4 substrate with hepatic extraction ratio 0.3–0.5 (Trouvin et al., 1988)] in morbidly obese patients showed no change in systemic clearance but decreased oral clearance of midazolam compared with that in healthy volunteers (Brill et al., 2014). On the other hand, the systemic clearance of triazolam (a CYP3A4 substrate of intermediate hepatic extraction ratio) after intravenous dose did not differ between obese subjects and those with normal weight (Derry et al., 1995). In human liver tissues, CYP3A4 protein levels in liver biopsies collected from obese patients (during laparoscopic gastric bypass or biliopancreatic diversion surgery) were negatively correlated with patients body mass index (Ulvestad et al., 2013), indicating repressive effects of obesity on CYP3A4 expression. Considering that morbid obesity is often accompanied by comorbidity (e.g., diabetes) that incurs chronic hepatic inflammation, decreased CYP3A4 expression in the liver tissues may result in part from underlying inflammation in obese subjects. Definitive evidence on how increased body weight impacts hepatic CYP3A4 expression in the absence of inflammation in humans is currently lacking.

To summarize, results from our diet-induced obesity model in Tg-CYP2D6 mice and comparison against clinical data suggest that obesity will likely have minimal effects on CYP2D6-mediated drug

metabolism. Together, results from this study provide insight into how obesity may impact hepatic drug disposition.

Department of Pharmacy Practice
(H.J.) and Department of
Biopharmaceutical Sciences (M.N.,
H.J.), College of Pharmacy,
University of Illinois at Chicago,
Chicago, Illinois

MIAORAN NING
HYUNYOUNG JEONG

Authorship Contributions

Participated in research design: Ning, Jeong.

Conducted experiments: Ning.

Performed data analysis: Ning, Jeong.

Wrote or contributed to the writing of the manuscript: Ning, Jeong.

References

- Aitken AE, Richardson TA, and Morgan ET (2006) Regulation of drug-metabolizing enzymes and transporters in inflammation. *Annu Rev Pharmacol Toxicol* 46:123–149.
- Bian H, Hakkarainen A, Lundbom N, and Yki-Järvinen H (2014) Effects of dietary interventions on liver volume in humans. *Obesity (Silver Spring)* 22:989–995.
- Björkholm B, Bok CM, Lundin A, Raftar J, Hibberd ML, and Pettersson S (2009) Intestinal microbiota regulate xenobiotic metabolism in the liver. *PLoS One* 4:e6958.
- Brill MJ, van Rongen A, Houwink AP, Burggraaf J, van Ramshorst B, Wiezer RJ, van Dongen EP, and Knibbe CA (2014) Midazolam pharmacokinetics in morbidly obese patients following semi-simultaneous oral and intravenous administration: a comparison with healthy volunteers. *Clin Pharmacokinet* 53:931–941.
- Cheymol G, Weissenburger J, Poirier JM, and Gelle C (1995) The pharmacokinetics of dexfenfluramine in obese and non-obese subjects. *Br J Clin Pharmacol* 39:684–687.
- Derry CL, Kroboth PD, Pittenger AL, Kroboth FJ, Corey SE, and Smith RB (1995) Pharmacokinetics and pharmacodynamics of triazolam after two intermittent doses in obese and normal-weight men. *J Clin Psychopharmacol* 15:197–205.
- Fang B, Mane-Padros D, Bolotin E, Jiang T, and Sladek FM (2012) Identification of a binding motif specific to HNF4 by comparative analysis of multiple nuclear receptors. *Nucleic Acids Res* 40:5343–5356.
- Fujioka K (2015) Current and emerging medications for overweight or obesity in people with comorbidities. *Diabetes Obes Metab* 17:1021–1032.
- Geng T, Xia L, Russo S, Kamara D, and Cowart LA (2015) Prostate-specific genes are associated with unsaturated fat suppression of saturated fat-induced hepatic steatosis in C57BL/6 mice. *Nutr Res* 35:812–822.

- Ghose R, Omoluabi O, Gandhi A, Shah P, Strohecker K, Carpenter KC, McFarlin B, and Guo T (2011) Role of high-fat diet in regulation of gene expression of drug metabolizing enzymes and transporters. *Life Sci* **89**:57–64.
- Hayhurst GP, Lee YH, Lambert G, Ward JM, and Gonzalez FJ (2001) Hepatocyte nuclear factor 4alpha (nuclear receptor 2A1) is essential for maintenance of hepatic gene expression and lipid homeostasis. *Mol Cell Biol* **21**:1393–1403.
- Johnson TN, Tucker GT, Tanner MS, and Rostami-Hodjegan A (2005) Changes in liver volume from birth to adulthood: a meta-analysis. *Liver Transpl* **11**:1481–1493.
- Jover R, Moya M, and Gómez-Lechón MJ (2009) Transcriptional regulation of cytochrome p450 genes by the nuclear receptor hepatocyte nuclear factor 4-alpha. *Curr Drug Metab* **10**:508–519.
- Kim S, Sohn I, Ahn JI, Lee KH, Lee YS, and Lee YS (2004) Hepatic gene expression profiles in a long-term high-fat diet-induced obesity mouse model. *Gene* **340**:99–109.
- Koh KH, Pan X, Shen HW, Arnold SL, Yu AM, Gonzalez FJ, Isoherranen N, and Jeong H (2014) Altered expression of small heterodimer partner governs cytochrome P450 (CYP) 2D6 induction during pregnancy in CYP2D6-humanized mice. *J Biol Chem* **289**:3105–3113.
- Kudo T, Shimada T, Toda T, Igeta S, Suzuki W, Ikarashi N, Ochiai W, Ito K, Aburada M, and Sugiyama K (2009) Altered expression of CYP in TSOD mice: a model of type 2 diabetes and obesity. *Xenobiotica* **39**:889–902.
- Lewis MC, Phillips ML, Slavotinek JP, Kow L, Thompson CH, and Toouli J (2006) Change in liver size and fat content after treatment with Optifast very low calorie diet. *Obes Surg* **16**:697–701.
- Li CY, Renaud HJ, Klaassen CD, and Cui JY (2016) Age-specific regulation of drug-processing genes in mouse liver by ligands of xenobiotic-sensing transcription factors. *Drug Metab Dispos* **44**:1038–1049.
- Martinez-Jimenez CP, Kymrzi I, Cardot P, Gonzalez FJ, and Talianidis I (2010) Hepatocyte nuclear factor 4alpha coordinates a transcription factor network regulating hepatic fatty acid metabolism. *Mol Cell Biol* **30**:565–577.
- Miao J, Xiao Z, Kanamaluru D, Min G, Yau PM, Veenstra TD, Ellis E, Strom S, Suino-Powell K, Xu HE, et al. (2009) Bile acid signaling pathways increase stability of small heterodimer partner (SHP) by inhibiting ubiquitin-proteasomal degradation. *Genes Dev* **23**:986–996.
- Müller VM, Zietek T, Rohm F, Fiamoncini J, Lagkouvardos I, Haller D, Clavel T, and Daniel H (2016) Gut barrier impairment by high-fat diet in mice depends on housing conditions. *Mol Nutr Food Res* **60**:897–908.
- Pan X, Lee YK, and Jeong H (2015) Farnesoid X receptor agonist represses cytochrome P450 2D6 expression by upregulating small heterodimer partner. *Drug Metab Dispos* **43**:1002–1007.
- Swierczynska MM, Mateska I, Peitzsch M, Bornstein SR, Chavakis T, Eisenhofer G, Lamounier-Zepter V, and Eaton S (2015) Changes in morphology and function of adrenal cortex in mice fed a high-fat diet. *Int J Obes* **39**:321–330.
- Trouvin JH, Farinotti R, Haberer JP, Servin F, Chauvin M, and Duvaldestin P (1988) Pharmacokinetics of midazolam in anaesthetized cirrhotic patients. *Br J Anaesth* **60**:762–767.
- Ulvestad M, Skottheim IB, Jakobsen GS, Bremer S, Molden E, Asberg A, Hjelmæsæth J, Andersson TB, Sandbu R, and Christensen H (2013) Impact of OATP1B1, MDR1, and CYP3A4 expression in liver and intestine on interpatient pharmacokinetic variability of atorvastatin in obese subjects. *Clin Pharmacol Ther* **93**:275–282.
- Ussar S, Griffin NW, Bezy O, Fujisaka S, Vienberg S, Softic S, Deng L, Bry L, Gordon JI, and Kahn CR (2015) Interactions between gut microbiota, host genetics and diet modulate the predisposition to obesity and metabolic syndrome. *Cell Metab* **22**:516–530.
- Wahlang B, Song M, Beier JI, Cameron Falkner K, Al-Eryani L, Clair HB, Prough RA, Osborne TS, Malarkey DE, and Christopher States J, and Cave MC (2014) Evaluation of Aroclor 1260 exposure in a mouse model of diet-induced obesity and non-alcoholic fatty liver disease. *Toxicol Appl Pharmacol* **279**:380–390.
- Wahlström A, Sayin SI, Marschall HU, and Bäckhed F (2016) Intestinal crosstalk between bile acids and microbiota and its impact on host metabolism. *Cell Metab* **24**:41–50.
- Xu Y, Zalzal M, Xu J, Li Y, Yin L, and Zhang Y (2015) A metabolic stress-inducible miR-34a-HNF4α pathway regulates lipid and lipoprotein metabolism. *Nat Commun* **6**:7466.
- Yoshinari K, Takagi S, Yoshimasa T, Sugatani J, and Miwa M (2006) Hepatic CYP3A expression is attenuated in obese mice fed a high-fat diet. *Pharm Res* **23**:1188–1200.

Address correspondence to: Dr. Hyunyoung Jeong, Department of Pharmacy Practice (MC 886), College of Pharmacy, University of Illinois at Chicago, 833 S. Wood Street, Chicago, IL 60612. E-mail: yjeong@uic.edu